The Myxoid Liposarcoma drugs in development market research report provides comprehensive information on the therapeutics under development for Myxoid Liposarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Myxoid Liposarcoma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Myxoid Liposarcoma and features dormant and discontinued products.
GlobalData tracks 20 drugs in development for Myxoid Liposarcoma by 16 companies/universities/institutes. The top development phase for Myxoid Liposarcoma is phase ii with 15 drugs in that stage. The Myxoid Liposarcoma pipeline has 19 drugs in development by companies and one by universities/ institutes. Some of the companies in the Myxoid Liposarcoma pipeline products market are: Agenus, Pharma Mar and Merck.
The key targets in the Myxoid Liposarcoma pipeline products market include Cancer/Testis Antigen 1, Programmed Cell Death Protein 1, and DNA.
The key mechanisms of action in the Myxoid Liposarcoma pipeline product include Programmed Cell Death Protein 1 Antagonist with three drugs in Phase II. The Myxoid Liposarcoma pipeline products include nine routes of administration with the top ROA being Intravenous and six key molecule types in the Myxoid Liposarcoma pipeline products market including Small Molecule, and Monoclonal Antibody.
Myxoid Liposarcoma overview
A myxoid liposarcoma is a malignant adipose tissue neoplasm of myxoid appearance histologically. Myxoid/round cell liposarcoma, or MRCLS, is one of several types of liposarcoma. Liposarcoma is a rare cancer that grows in the cells that store fat in the body. MRCLS usually grows in the arms and legs. These tumors grow slowly, and they can spread to other parts of the body.
For a complete picture of Myxoid Liposarcoma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
